Evidence map›Paper›PMID 17226897›Full record

ReviewWorld journal of gastroenterology2007

Early diabetic neuropathy: triggers and mechanisms.

Maxim Dobretsov, Dmitry Romanovsky, Joseph R Stimers

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in World journal of gastroenterology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04833660 (The Effect of Repetitive Transcranial Magnetic Stimulation on Diabetic Peripheral Neuropathic Pain), which is not on this map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04833660 naunknown statusnot on this mapstarted 2021, after this paper: background citation

The Effect of Repetitive Transcranial Magnetic Stimulation on Diabetic Peripheral Neuropathic Pain: A Randomized Controlled Trial

TypeinterventionalSponsorMin Cheol ChangRan2021 to 2021Enrolled22ConditionsDiabetic Peripheral Neuropathic PainArmsrepetitive transcranial magnetic stimulation
3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 150 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Neuropad Assessment of Sudomotor Function Across Glycemic Levels in Adults.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025
    Article
  8. Review
  9. Article
  10. Novel drugs affecting diabetic peripheral neuropathy.Iranian journal of basic medical sciences · 2024
    Review
  11. Review
  12. Article
  13. Article
  14. Advanced Glycation End-Products in Skeletal Muscle Aging.Bioengineering (Basel, Switzerland) · 2021
    Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Maxim DobretsovDepartment of Anesthesiology, Slot 515, University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205, United States. dobretsovmaxim@uams.edu
Dmitry Romanovsky
Joseph R Stimers
University of Arkansas for Medical Sciences · US

Funding

Hyperglycemia-Induced Mechanical HyperalgesiaR01DK067284 · NIDDK · UNIV OF ARKANSAS FOR MED SCIS · PI DOBRETSOV, MAXIM · 2004 to 2006
$849k
NIDDK NIH HHS DK067248NIDDK NIH HHS R01 DK067284-01NIDDK NIH HHS R01 DK067284-02NIDDK NIH HHS R01 DK067284-03
6 · The paper itself

Abstract

Peripheral neuropathy, and specifically distal peripheral neuropathy (DPN), is one of the most frequent and troublesome complications of diabetes mellitus. It is the major reason for morbidity and mortality among diabetic patients. It is also frequently associated with debilitating pain. Unfortunately, our knowledge of the natural history and pathogenesis of this disease remains limited. For a long time hyperglycemia was viewed as a major, if not the sole factor, responsible for all symptomatic presentations of DPN. Multiple clinical observations and animal studies supported this view. The control of blood glucose as an obligatory step of therapy to delay or reverse DPN is no longer an arguable issue. However, while supporting evidence for the glycemic hypothesis has accumulated, multiple controversies accumulated as well. It is obvious now that DPN cannot be fully understood without considering factors besides hyperglycemia. Some symptoms of DPN may develop with little, if any, correlation with the glycemic status of a patient. It is also clear that identification of these putative non-glycemic mechanisms of DPN is of utmost importance for our understanding of failures with existing treatments and for the development of new approaches for diagnosis and therapy of DPN. In this work we will review the strengths and weaknesses of the glycemic hypothesis, focusing on clinical and animal data and on the pathogenesis of early stages and triggers of DPN other than hyperglycemia.

Indexed as

AnimalsDiabetic NeuropathiesHumansHyperglycemiaInsulinSignal TransductionInsulin

Identifiers

PMID17226897
PMCPMC1829411
OpenAlexW2125179582

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.